Training activity information
Details
Analyse, interpret and report pharmacogenetic testing in oncology patients, to include
- DPYD
- MGMT
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- Best practice guidelines
- Local and national guidance
- Referral pathway
- Screening strategy
- Sequencing nomenclature
- Different methodologies
- Clinical and scientific basis, including adapting language to describe the interpretation appropriately
- Application of results to patient treatment
- Impact of ethnicity
- Limitation of methodologies
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Analyse, interpret and prepare interpretive reports of clinically relevant findings for patients with lung, central nervous system (CNS), sarcoma tumours, and somatic and germline variants in ovarian and breast cancer. |
| # 4 |
Outcome
Interpret QC data including bioinformatic and NGS quality metrics in relation to assay performance, EQA and ISO:15189 standards. |
| # 5 |
Outcome
Analyse, interpret and prepare interpretive reports for circulating tumour DNA (ctDNA) testing in lung cancer. |
| # 6 |
Outcome
Analyse, interpret and prepare interpretive pharmacogenetic reports in oncology patients. |